ArticleJAAD case reports2023
Resolution of therapy-resistant pyoderma gangrenosum with upadacitinib.
Article in JAAD case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 14 citations in OpenAlex.
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology.Medicina (Kaunas, Lithuania) · 2026Review
- JAK Inhibitors for Treatment of Pyoderma Gangrenosum and Sweet Syndrome: A Systematic Review of Published Case Reports.Dermatology research and practice · 2026Review
- Case Report: Treatment of facial pyoderma gangrenosum with Upadacitinib.Frontiers in medicine · 2025Article
- Successful Treatment of Severe Pyoderma Gangrenosum and Ulcerative Colitis With Upadacitinib.ACG case reports journal · 2024Article
- Positioning Crohn's Disease Therapies in the Era of Small Molecules and Combination Therapies.Current gastroenterology reports · 2024Review
- Tofacitinib therapy for severe pyoderma gangrenosum in a patient with enteropathic arthritis: a case-based review.Rheumatology international · 2024Review
- Personalized Treatment for Crohn's Disease: Current Approaches and Future Directions.Clinical and experimental gastroenterology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.